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Fusions between the transmembrane protease serine 2 (TMPRSS2) and ETS related gene (ERG)
represent one of themost specific biomarkers that define a distinct molecular subtype of pros-
tate cancer. Studies of TMPRSS2-ERG gene fusions have seldom been performed at the protein
level, primarily due to the lack of high-quality antibodies suitable for quantitative studies. Here-
in, we applied a recently developed PRISM (high-pressure high-resolution separations with
intelligent selection and multiplexing)-SRM (selected reaction monitoring) strategy for quanti-
fying ERG protein in prostate cancer cell lines and tumors. The highly sensitive PRISM-SRM as-
says provided confident detection of 6 unique ERG peptides in both TMPRSS2-ERG positive cell
linesandtissues, butnot incell linesor tissues lacking theTMPRSS2-ERGrearrangement,clearly
indicating thatERGproteinexpression issignificantly increased in thepresenceof theTMPRSS2-
ERG gene fusion. Significantly, our results provide evidence that two distinct ERG protein iso-
forms are simultaneously expressed in TMPRSS2-ERG positive samples as evidenced by the
concomitant detection of two mutually exclusive peptides in two patient tumors and in the
VCaP prostate cancer cell line. Three peptides, shared across almost all fusion protein products,
weredeterminedtobe themost abundantpeptides, providing “signature”peptides fordetection
of ERG over-expression resulting from TMPRSS2-ERG gene fusion. The PRISM-SRM assays pro-
vide valuable tools for studying TMPRSS2-ERG gene fusion protein products in prostate cancer.
ª 2014 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.protease serine 2; ERG, ETS related gene; FISH, fluorescence in situ hybridization; SRM,
ressure high-resolution separations with intelligent selection and multiplexing; LOD, limit
C, extracted ion chromatogram; CV, coefficient of variation.
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MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 1 6 9e1 1 8 011701. Introduction analysis and the assay sensitivity was greatly increased. AThe identification of gene fusion events between the
androgen-responsive transmembrane protease serine 2
(TMPRSS2) 50 region and the proliferation-associated ETS
related gene (ERG) transcription factor in over 50% of prostate
cancers (Kumar-Sinha et al., 2008; Mosquera et al., 2009;
Tomlins et al., 2008, 2005) has provided novel insights into
the possible mechanisms of prostate cancer progression, by
providing a direct link between androgen sensitivity and
proliferation-associated changes in gene expression (St John
et al., 2012). However, despite the mechanistic significance
of this observation, most studies of the TMPRSS2-ERG gene
fusion to date have relied upon observations at the gene level,
using either fluorescence in situ hybridization (FISH) to iden-
tify the chromosomal translocation, or fusion-specific PCR to
identify fusion transcripts (Demichelis et al., 2007; Maher
et al., 2009; Perner et al., 2006; Tomlins et al., 2005). Since the
hypothetical role of TMPRSS2-ERG gene fusions in prostate
carcinogenesis is dependent on the transcription activating
functions of the ERG gene product, it is important to both
verify the protein-level expression of the TMPRSS2-ERG gene
fusion and quantify the levels of protein expression in tumors
of varying stage, grade, and outcome. The TMPRSS2-ERG
fusion gene encodes a truncated ERG protein and the study
of TMPRSS2-ERG gene fusion at the protein level will
contribute to the understanding of the roles of this protein
in critical signaling pathways in prostate cancer such as the
androgen signaling pathway and the phosphoinositide 3-
kinase (PI3K) pathway (Zong et al., 2009). To date, most of
the published data on ERG protein expression has relied on
immunohistochemical detection of this protein in tissue sam-
ples (Falzarano et al., 2011; Furusato et al., 2010; Park et al.,
2010; van Leenders et al., 2011). Moreover, these ERG anti-
bodies cannot distinguish between various versions of the
ERG protein, such as the different isoforms generated by
distinct fusion sites and alternative splicing.
The availability of a sensitive, robust, and antibody-
independent method for identifying and quantifying individ-
ual peptides within ERG that are differentially present in the
various gene fusion-specific isoforms would provide re-
searchers with a useful tool for prognostic and mechanistic
studies of the potential role of truncated ERG proteins in pros-
tate cancer development and progression. Unlike immunoas-
says, mass spectrometry (MS)-based assays can be completely
independent of antibodies. Selected reaction monitoring
(SRM)-MS represents a major advance in both sensitivity and
specificity for quantitative analysis of target proteins and
has frequently been used as an alternative to antibody-
based assays (Addona et al., 2009; Anderson and Hunter,
2006; Gerber et al., 2003; Huttenhain et al., 2012; Keshishian
et al., 2009; Picotti et al., 2009, 2013; Simicevic et al., 2013).
However, the sensitivity of conventional SRM is still insuffi-
cient to allow for accurate measurement of some extremely
low-abundance proteins, such as ERG protein. To improve
the sensitivity of SRM-based assays, Anderson and colleagues
(Anderson et al., 2004; Kuhn et al., 2012;Whiteaker et al., 2010)
have developed a SISCAPA method where target peptides
were enriched using anti-peptide antibodies prior to SRMmajor limitation of the SISCAPA method was that it required
generation of high-quality antibodies against target peptides,
introducing many of the same challenges restricting typical
antibody production, e.g., moderate success rates and long
lead times. More recently, our group has developed an
antibody-independent PRISM (high-pressure high-resolution
separations with intelligent selection and multiplexing)-SRM
strategy where target peptides were enriched using high pH
reversed-phase (RP) LC prior to the second dimension LC-
SRM analysis (Shi et al., 2012). This method improved the
sensitivity of target protein detection and quantification by
at least 100-fold compared with conventional SRM.
In this study we have developed a series of targeted PRISM-
SRM assays capable of specifically recognizing 16 distinct pep-
tides from various domains of TMPRSS2-ERG gene fusion pro-
tein products, and demonstrated expression of seven of these
peptides in TMPRSS2-ERG positive prostate cancer cell lines
and patient-derived tumor samples. These results provide
quantitative and isoform-specific information about ERG pro-
tein expression in prostate cancer cells and tumors; applica-
tion of these assays for measurements of the TMPRSS2-ERG
gene fusion protein products in large patient cohorts has the
potential to significantly enhance our understanding of the
role of ERG protein in the biology of prostate cancer.2. Materials and methods
2.1. Prostate cancer cell line and tissue samples
Six prostate cancer cell lines were analyzed in this study,
including two TMPRSS2-ERG gene fusion positive cell lines,
VCaP and NCI-H660, as well as four TMPRSS2-ERG gene fusion
negative cell lines LNCaP, DU145, PC3 and 22RV1. All cell lines
were purchased from the American Type Culture Collection
(Manassas, VA). Ten metastatic castration-resistant prostate
cancer (CRPC) tissue sampleswere also analyzed in this study,
including five TMPRSS2-ERG gene fusion positive tissues PT1e
PT5 and five TMPRSS2-ERG gene fusion negative tissues NT1 e
NT5 provided by the University of Michigan, Ann Arbor (J. Wei
and A. Chinnaiyan). For detailed information about these
samples, refer to the previous publication by Grasso et al.
(2012). Two additional TMPRSS2-ERG gene fusion positive
localized prostate cancer tissues PT6 and PT7 were provided
by Weill Cornell Medical College (M. Rubin). The information
of the 12 tissue samples is listed in Table S1. All experimental
procedures were approved by the Institutional Review Boards
of the University of Michigan (Ann Arbor, MI), Cornell Univer-
sity (New York, NY), and Pacific Northwest National Labora-
tory (Richland, WA) in accordance with federal regulations.
2.2. Protein extraction and digestion
Proteins were extracted from each cell line using a urea solu-
tion (8 M urea in 50 mM NH4HCO3). Cells were sonicated for
1min twice and the protein concentrationwas determinedus-
ing the bicinchoninic acid (BCA) assay (Pierce). Proteins in
each cell line sample were reduced with 10 mM dithiothreitol
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room temperature for 1 h in the dark. Samples were diluted
10-fold with 50 mM NH4HCO3 and 1 M CaCl2 was added to
each sample to reach a concentration of 1 mM. Protein diges-
tion was performed at 37 C for 3 h using trypsin (Affymetrix,
Santa Clara, CA) at a 1:50 ratio (w/w). Each sample was
desalted using a C18 SPE column (Discovery DSC-18, SUPELCO,
Bellefonte, PA) and concentrated to a volume of w50 mL. The
peptide concentration was measured using the BCA assay.
Samples were stored at 80 C.
A different procedure was used to process the tumor tissue
samples obtained by coring of OCT frozen tissue blocks.
Briefly, a lysis buffer containing 8 M urea, 75 mM NaCl, prote-
ase inhibitor cocktail (SigmaeAldrich, St. Louis, MO), complete
protease inhibitor tablet (Roche,Mannheim, Germany), 50mM
NH4HCO3, pH 7.8, was used to lyse tissues. Samples were son-
icated for 3 min and the protein concentration was deter-
mined using the BCA assay. Proteins in each tissue sample
were reduced with 5 mM dithiothreitol at 37 C for 1 h and
alkylated using 10 mM iodoacetamide at room temperature
for 1 h in the dark. CaCl2 was added to each sample to obtain
a final concentration of 1 mM. Protein digestion was per-
formed at 37 C overnight at a 1:50 ratio (w/w). Tryptic diges-
tion was quenched using trifluoroacetic acid (final pH:
2e2.5). Each sample was desalted using a SCX SPE column
(Discovery DSC-SCX, SUPELCO, Bellefonte, PA). The peptide
concentration was measured using the BCA assay. Samples
were stored at 80 C for future analysis.
2.3. SRM assay development
Sixteen proteotypic peptides (Table S2) covering different
sequence regions of various TMPRSS2-ERG gene fusion pro-
tein products were selected and stable isotope-labeled heavy
peptides with C-terminal [13C6
15N2] lysine or [
13C6
15N4] argi-
nine were synthesized (Thermo Fisher Scientific) for SRM
assay development. The peptides were selected following
the standard criteria as described by Aebersold and co-
workers (Lange et al., 2008). The purity of these synthetic pep-
tides was >97% as determined by amino acid analysis (AAA).
SRM parameters were optimized by direct infusion experi-
ments on a TSQ Quantum Ultra triple quadrupole mass spec-
trometer (Thermo Fisher Scientific), where the 6e8 most
intense fragment ions for each peptide were selected as
precursor-to-fragment transitions and the collision energy
(CE) of each transition was optimized automatically in SRM
mode. The peptides were dissolved in a buffer containing
50% acetonitrile and 0.1% formic acid and the infusion rate
was 300 nL/min.
The transitions and corresponding optimal CE values from
the infusion experiments were further validated for optimal
detection of the target peptides in actual LC-SRM analysis. In
this step 50 fmol/mL of heavy peptide standards were spiked
with 0.5 mg/mL of VCaP-derived tryptic peptides and 2 mL of
the sample were analyzed using a nanoACQUITY UPLC sys-
tem (Waters Corporation, Milford, MA) and a TSQ Vantage tri-
ple quadrupole mass spectrometer (Thermo Fisher Scientific).
A transition with a low intensity or a high level of interference
was not selected. Three transitions per peptide were retained
for the final SRM assays.2.4. PRISM fractionation
Five fmol/mL of high-purity heavy peptides (purity > 97%) were
spikedwith 1 mg/mL of peptides fromeach cell line or tissue sam-
ple and the peptides were separated following the PRISMwork-
flow using high pH reversed-phase capillary LC on a
nanoACQUITY UPLC system as described previously (Shi
et al., 2012). Briefly, separationswereperformedusingacapillary
column packed in house (3 mm Jupiter C18 bonded particles,
200 mm i.d.  50 cm long) at a flow rate of 3.3 mL/min on binary
pumpsystems, using 10mMammoniumformate (pH10) asmo-
bile phase A and 10mMammonium formate in 90% acetonitrile
(pH 10) as mobile phase B. Forty-five microliters of each sample
(1 mg/mL) were loaded onto the column and separated using a bi-
nary gradient of 5e15%B in 15min, 15e25%B in 25min, 25e45%
Bin25min, and45e90%B in38min. Following theLCseparation,
the eluent from the capillary column was split into two flowing
streams (1:10split) viaaTeeunion.Thesmaller fractionofeluent
was sent at a flow rate of 300nL/min to aTSQQuantumUltra tri-
ple quadrupole mass spectrometer for on-line SRMmonitoring
of heavy peptide standards. TSQ Quantum Ultra was operated
with ion spray voltages of 2400 100 V, a capillary offset voltage
of 35 V, a skimmer offset voltage of 5 V, and a capillary inlet
temperature of 220 C. Tube lens voltages were obtained from
automatic tuning and calibration without further optimization.
Both Q1 and Q3 were set at unit resolution of 0.7 FWHM and
Q2 gas pressure was 1.5 mTorr. A scan width of 0.002m/z and a
dwell time of 10 ms were used. A large fraction of the capillary
column eluent flowing at a rate of 3 mL/min was automatically
collected every 1min into a 96-well plate using a Triversa Nano-
Mate system (Advion BioSciences, Ithaca, NY) over the course
ofw100 min LC separation. Prior to peptide fraction collection,
17 mL of water was added to each well in the plate to avoid pep-
tide loss and also to dilute the peptide fraction for LC-SRM anal-
ysis. The fraction containing a target peptide was intelligently
selected based on the retention time of the peptide obtained by
on-linemonitoring.Thedetailedmethod for intelligent selection
was described in our previous study (Shi et al., 2012).
2.5. LC-SRM analysis
Following high pH capillary RPLC separation and intelligent
selection, the fractions containing the target peptides were
subjected to LC-SRM analysis. All peptide fractions were
analyzed using a nanoACQUITY UPLC system coupled on-
line to a TSQ Vantage triple quadrupole mass spectrometer.
The UPLC system was equipped with an ACQUITY UPLC
BEH 1.7 mm C18 column (75 mm i.d.  25 cm), which was con-
nected to a chemically etched 20 mm i.d. fused-silica emitter
via a Valco stainless steel union. Four microliters of each pep-
tide fraction were loaded onto the column at a flow rate of
1 mL/min for 5 min. Peptides were separated at a flow rate of
500 nL/min using a 10min linear gradient from 5 to 65% aceto-
nitrile in water. The TSQ Vantage was operated in the same
manner as the TSQ Quantum Ultra.
2.6. Calibration curve experiments
Tryptic peptides from four TMPRSS2-ERG negative tissue
samples were pooled and used as the matrix for the
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spiked into the matrix at a constant concentration of 5 fmol/
mL, while light peptides (purity >97%) were spiked at 0, 0.5, 1,
2, 5, 10, 20, 50, 100 and 500 amol/mL levels. The concentration
of peptide mixture in each individual data point was adjusted
to 1 mg/mL. All spike-in samples were analyzed using the same
PRISM-SRM method used for analysis of prostate cancer cell
line and tumor tissue samples as mentioned above. Light to
heavy peak area ratios were plotted against the correspond-
ing light peptide concentration values to build a calibration
curve for each peptide. The limit of detection (LOD) and limit
of quantification (LOQ) were defined as the lowest concentra-
tion point of target peptides at which the S/N of surrogate
peptides was at least 3 and 10, respectively. Signal to noise ra-
tio (S/N) was calculated by the peak apex intensity over the
highest background noise in a retention time region of 10 s
for the target peptides.
2.7. Data analysis
The rawdataacquiredontheTSQVantage triple quadrupoleMS
were initially imported into Skyline software (MacLean et al.,
2010) for visualization of chromatograms of target peptides
and to determinewhich peptides can be detected. The detected
peptides were further quantified using Xcalibur 2.0.7 (Thermo
FisherScientific).Themostabundant transition foreachpeptide
was used for quantification unless interference was observed.
Peak detection and integration were based on two criteria: 1)
the same retention time and 2) approximately the same relative
peak intensity ratios across multiple transitions between light
peptide and heavy peptide standards. All data were manually
inspectedtoensure correctpeakdetectionandaccurate integra-
tion. Light toheavypeakarea ratioswere used toquantify target
peptides. The expression level of each peptide in cell line or tis-
sue samples (amol/mg of total protein) was calculated by the
following equation: (amol/mL concentration of endogenous
target peptide calculated based on calibration curve)  (mL
loading volume on-column)/(mg loading amount on-column).
Extracted ionchromatograms (XICs)werecreatedusingSkyline.3. Results
3.1. Study design
The goal of this study was to accurately detect and quantify
TMPRSS-ERG fusion products in prostate cancer at the protein
level. To achieve this goal, we have applied an antibody-
independent PRISM-SRM method. Briefly, a list of peptides
that uniquely represent ERG protein were selected and syn-
thesized for development of SRM assays, and then ERG-
derived target peptides in prostate cancer samples were
enriched and intelligently selected using PRISM and were
further quantified by LC-SRM. The workflow for this study is
summarized in Supplementary Figure S1.
3.2. Peptide selection and SRM assay development
The selection of peptides is a critical step in the development
of sensitive SRM assays. A commonly used criterion is toselect peptides that have previously been detected through
large-scale shotgun analyses (Picotti and Aebersold, 2012).
However, the transcriptional regulator ERG is such a low
abundance protein that it has not been detected in either
our internal shotgun data sets or publicly available databases
such as PeptideAtlas (Desiere et al., 2005). To ensure that ERG
protein can be detected with high sensitivity, we selected 16
unique peptides covering different sequence regions of
various ERG protein isoforms. Four out of the 16 peptides are
shared by almost all ERG isoforms while the other 12 peptides
are less common (Table 1).
SRMparametersweremanuallyoptimizedbydirect infusion
to ensure high sensitivity of SRM assays. The 6 most intense
transitions of eachpeptide resulting from the infusion analyses
were further inspected by LC-SRMwhere VCaP lysate was used
asmatrix. The transitions showing low intensity signals or high
levels of interference were eliminated. Finally, the top 3 transi-
tions were selected for monitoring each target peptide. The
transitions for the 16 peptides and the corresponding optimal
collision energy for each transition are listed in Table S2.
3.3. Detection of multiple isoforms of ERG protein in
TMPRSS2-ERG gene fusion positive prostate cancer cell lines
and tumor tissues
Using the PRISM-SRM strategy, TMPRSS2-ERG fusions were
detected at the protein level in TMPRSS2-ERG gene fusion posi-
tiveprostate cancer cell lines and tumor tissueswith confirmed
fusions at the genome level.
A total of 9 TMPRSS2-ERG gene fusion positive controls
were included in this study, where 2 were cell lines (VCaP
and NCI-H660) and 7 were prostate tumor tissues (PT1 to
PT7). SRM monitoring of the 16 selected peptides showed
that multiple peptides were simultaneously detected in 8
out of the 9 positive controls. The only exception was the
tissue sample PT3 where only 1 unique peptide was
detected.
Substantial expression of ERG protein was observed in the
VCaP cell line, one of the most extensively used in vitro
models for TMPRSS2-ERG gene fusion. Figure 1A depicts
XICs of transitions monitored for the 6 peptides detected in
the VCaP cell line, where the bottom panel indicates the re-
sponses of the endogenous ERG peptides. Interestingly, pep-
tide VIVPADPTLWSTDHVR showed w50- to 100-fold higher
response than the other peptides in the VCaP cell line. In
the NCI-H660 cell line, only 2 ERG-derived peptides were
detected and the responses of these peptides were w10-
fold lower than those in the VCaP cell line (Supplementary
Figure S2).
ERG proteinwas also detected in TMPRSS2-ERG gene fusion
positive prostate tumor tissues. As an example, Figure 1B
demonstrates that 5 unique ERG peptides were detected in
sample PT1 where peptide VIVPADPTLWSTDHVR again dis-
played the highest response. ERG protein was also detected
in all the other 6 TMPRSS2-ERG positive tissue samples
(Supplementary Figure S3), indicating that the expression of
ERG protein may be a common feature for prostate cancer pa-
tients with the TMPRSS2-ERG gene fusion.
Overall, a total of 7 unique ERG peptides were detected in
TMPRSS2-ERG positive samples; 5 of these were consistently
Table 1 e ERG-derived peptides selected for PRISM-SRM assays as well as their expression in various ERG protein isoforms. “X” means the
ERG protein isoform listed in a row contained the peptide listed in a certain column. The peptides detected in this study were highlighted in
either green or red. The peptides not detected were shown in black. The two peptides highlighted in red are mutually exclusive in each ERG
isoform.
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thesepeptides tovarious isoformsofERGproteinwhere theexon
information was included (Supplementary Figure S4). While
most of the detected peptides are encoded by different exons,
peptides MVGSPDTVGMNYGSYMEEK and HMPPPNMTTNER are
translated from the same exon (exon 7). Of significance was
that peptides ITTRPDLPYEPPR and NTDLPYEPPR are mutually
exclusive; that no single isoform contains both of these peptides
(highlighted in red in Table 1; Figure S4). The detection of both
ITTRPDLPYEPPR and NTDLPYEPPR in the VCaP cell line as well
as in the PT1 and PT2 tissues indicated that at least two distinctisoforms of ERG proteinwere simultaneously expressed in these
TMPRSS2-ERG positive samples.
3.4. Quantification of ERG-derived peptides in prostate
cancer cell lines and tumor tissues
The abundance of a target peptide can be determined by
the peak area ratio of light (endogenous) peptide to a heavy
peptide standard spiked into each sample at known concen-
tration. In this study the most abundant transition for each
peptide was used for quantification. The peak area ratios of
Figure 1 eMultiple peptides derived from ERG protein are simultaneously detected in TMPRSS2-ERG gene fusion positive prostate cancer cell
line VCaP (A) and tumor tissue PT1 (B). The transitions monitored for each peptide were plotted as overlaid extracted ion chromatograms (XICs).
XICs of a target peptide (Light) and the corresponding heavy internal standard (Heavy) were shown as a group where the peptide sequence was
indicated on top of each group. All peptides were analyzed in triplicate and one representative XIC for each peptide was shown here.
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samples are listed in Table S3. These values ranged from
0.00027 to 0.26. We also calculated the coefficient of variation
(CV) values based on the peak area ratio values for each pep-
tide in triplicate measurements of each cell line and patientsample. The observed CV values across almost all samples
were less than 15% (Table S3), suggesting that high reliability
was achievable with our SRM assays.
To accurately quantify the ERG-derived peptides, we built a
calibration curve and determined the LOD and LOQ values for
Figure 2 e Calibration curve of peptide VIVPADPTLWSTDHVR.
The light to heavy peak area ratio of the transition m/z 602.66/
747.87 was plotted against the corresponding light peptide
concentration (amol/mL). The heavy peptide standard was
consistently spiked at 5 fmol/mL. Nine data points were used to build
the curve, where each data point was measured in triplicate. Error
bars represent standard deviation of three measurements for each data
point. The insert plot shows a more detailed view of lower end of the
curve.
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where a tryptic peptide mixture of 4 TMPRSS2-ERG negative
tissue samples was used as matrix (see “Experimental Proce-
dures” for details of this experiment). Figure 2 shows the cali-
bration curve of peptide VIVPADPTLWSTDHVR based on the
transition 602.66 / 747.87. Excellent linearity was observed
over a concentration range of 2e500 amol/mL. The
peptide can still be detected at a concentration as low as
0.5 amol/mL, but the response becomes nonlinear when the
concentration is lower than 2 amol/mL. Based on these obser-
vations, we concluded that the peptide VIVPADPTLWSTDHVR
had an LOD of 0.5 amol/mg of total protein and an LOQ of
2 amol/mg of total protein, which are equivalent to 4.5 amol
and 18 amol of peptide on column for LOD and LOQ, respec-
tively. The calibration curves of all the other 6 detected ERG
peptides are shown in Supplementary Figure S5. The LOD
for these peptides ranged from 4.5 to 45 amol or 0.5 to
5 amol/mg of total protein, and the LOQ ranged from 18 to
450 amol or 2 to 50 amol/mg of total protein (Table 2).
We quantified those ERG-derived peptides based on the
peak area ratio values and the calibration curves, where the
expression level of each peptide was represented by amol/mg
of totalprotein.Thecalculationwasdescribed in“Experimental
Procedures”. Theexpression levels of the6peptidesdetected in
the TMPRSS2-ERG positive cell lines (VCaP and NCI-H660)
ranged from w20 to 1200 amol/mg of total protein (Table 3).
Similar ERG expression patterns were observed in prostatetumor tissue samples, where ERG-derived peptides were also
expressed at widely variable levels e ranging from w10 to
1200amol/mg of total protein in the 7TMPRSS2-ERGpositive tis-
sues (Table 4). The abundance of all 7 detected ERG peptides in
TMPRSS2-ERG positive cell lines and tissues was depicted in a
clustered bar chart (Supplementary Figure S6). Note that the
most abundant peptides were MVGSPDTVGMNYGSYMEEK,
HMPPPNMTTNER, and VIVPADPTLWSTDHVR that are shared
byalmostall ERG isoforms (Table1).Thesepeptidesaresuitable
as “signature” peptides for highly sensitive, highly specific
detection of ERG protein expression.
3.5. ERG protein expression is highly correlated with
ERG gene rearrangement
We also analyzed 9 TMPRSS2-ERG fusion negative controls,
including 4 classic prostate cancer cell lines (LNCaP, DU145,
PC3 and 22RV1) and 5 prostate tumor tissues. PRISM-SRM
analysis showed that none of the ERG unique peptides were
detected in the TMPRSS2-ERG negative samples with one
exception, sample NT2, which had low level expression of a
single peptide (Table 4). Figure 3 compares the expression pat-
terns of the ERG peptide VIVPADPTLWSTDHVR in TMPRSS2-
ERG gene fusion positive versus negative samples. While
this peptide was clearly detected in all TMPRSS2-ERG positive
cell lines (Figure 3A) and in 6 out of 7 TMPRSS2-ERG positive
tumor tissues (Figure 3B), it was not detected in the 4 negative
cell lines (Figure 3A) or the 5 negative tumor tissues (XICs not
shown). There was a consistently high correlation between
ERG protein levels, detected by PRISM-SRM, and the presence
of TMPRSS2-ERG gene rearrangements.4. Discussion
The TMPRSS2-ERG gene fusion represents one of the most
specific biomarkers for prostate cancer, having nearly 100%
specificity (Mosquera et al., 2009; Tomlins et al., 2009).
Numerous studies have demonstrated that TMPRSS2-ERG
transcripts are over-expressed in prostate cancer due to rear-
rangement of TMPRSS2 and ERG genes (Demichelis et al., 2007;
Perner et al., 2006; Tomlins et al., 2005). TMPRSS2-ERG tran-
scripts are translated into a truncated ERG protein product,
which may serve as a diagnostic marker for prostate cancer
and may also play a critical role in cell signaling (for example,
androgen signaling) involved in the development and progres-
sion of prostate cancer (Zong et al., 2009). However, most of
the studies on TMPRSS2-ERG gene fusion have thus far been
performed at the mRNA level rather than at the protein level
due to the lack of high-quality antibodies against ERG protein.
MS-based SRM assays provide a powerful alternative to
antibody-based assays for quantification of target proteins.
However, the sensitivity of conventional SRM is much less
than immunoassays and does not allow for detection of the
low-abundance ERG protein. Recently, our group developed
the 2D-LC-based PRISM-SRM strategy which allows for >100-
fold improvement in the sensitivity of target protein detection
and quantification (Shi et al., 2012). Using this method, we
successfully quantified ERG protein at levels as low as
w10 amol/mg of total protein in prostate tumor tissue samples
Table 2 e LOD and LOQ of each ERG peptide detected in this study.
Peptide Transitiona LOD LOQ
amol amol/mg total protein amol amol/mg total protein
TEMTASSSSDYGQTSK 840.36/ 1146.49 18 2 180 20
MECNPSQVNGSR 689.80/ 844.43 45 5 180 20
MVGSPDTVGMNYGSYMEEK 1047.94/ 1308.52 45 5 450 50
HMPPPNMTTNER 712.82/ 578.77 18 2 180 20
VIVPADPTLWSTDHVR 602.66/ 747.87 4.5 0.5 18 2
ITTRPDLPYEPPR 518.95/ 379.70 45 5 90 10
NTDLPYEPPR 601.30/ 758.38 45 5 90 10
a The transition that was used to determine LOD and LOQ values.
Table 3eQuantification of ERG peptides in ERGD and ERG- cell lines. The expression levels of these peptides were represented by amol/mg of
total protein. Each value represents the mean and standard deviation (SD) of three replicate measurements. VCaP andNCI-H660 are TMPRSS2-
ERG fusion positive cell lines; LNCaP, DU145, PC3 and 22RV1 are TMPRSS2-ERG fusion negative cell lines.
Sequence amol/mg of total protein
VCaP NCI-H660 LNCaP DU145 PC3 22RV1
MECNPSQVNGSR 189  20
MVGSPDTVGMNYGSYMEEK 618  26
HMPPPNMTTNER 1240  17 84  11
VIVPADPTLWSTDHVR 726  16 98  3
ITTRPDLPYEPPR 73  2
NTDLPYEPPR 17  1
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 1 6 9e1 1 8 01176(Table 4), and demonstrated superior sensitivity of PRISM-SRM
over in-house ERG antibodies in detecting recombinant ERG
proteins (unpublished results).
In addition to sensitivity, specificity is a key factor influ-
encing the accuracy of an assay. The specificity of immunoas-
says can be compromised due to cross-reactivity of antibodies
with nonspecific molecules. One of the major advantages of
an SRM assay over an immunoassay is its high specificity, as
the peptide sequence is confirmed at the product ion level.
In this study all 7 detected peptides are unique to ERG protein
as confirmed by a BLAST search. Moreover, both the parent
ion and several product ions were monitored for each unique
peptide in SRM analyses, which further improved theTable 4 e Quantification of ERG peptides in ERGD and ERG- tissues. T
total protein. Each value represents the mean and SD of three replicate m
lower than the LOQ and could not be accurately quantified. PT1-PT7 we
were TMPRSS2-ERG fusion negative prostate tumor tissues.
Sequence a
PT1 PT2 PT3 PT4
TEMTASSSSDYGQTSK
MVGSPDTVGMNYGSYMEEK 339  6 50  17 80  16 3
HMPPPNMTTNER 1210  35 169  34 17  4 78  12 7
VIVPADPTLWSTDHVR 48  1 NQ NQ
ITTRPDLPYEPPR 31  3 10  1
NTDLPYEPPR 26  2 10  1 NQanalytical specificity. Based on specific detection of peptides
uniquely representing our target protein ERG, we achieved
ultra-high specificity for ERG analyses.
In principle SRM-based assays can provide information on
protein isoforms by monitoring of isoform-specific peptides.
As shown in Table 1 and Figure S4, given the substantial
sequence homology among potential TMPRSS2-ERG gene
fusion protein products and the limited repertoire of specific
enzyme-cleavage (e.g., tryptic) peptides, it is difficult to distin-
guish among potential isoforms (in fact some TMPRSS2-ERG
fusions produce the same truncated ERG proteins; see Table 1
and Figure S4 for details). In addition the inability to detect
given isoform-specific peptide(s) does not exclude thehe expression levels of these peptides were represented by amol/mg of
easurements. NQ means the peptide was detected, but its amount was
re TMPRSS2-ERG fusion positive prostate tumor tissues; NT1-NT5
mol/mg of total protein
PT5 PT6 PT7 NT1 NT2 NT3 NT4 NT5
287  11
82  9 117  16 546  38
60  41 543  42 762  28 198  46
30  2 74  6 35  1
Figure 3 e Expression of an ERG derived peptide VIVPADPTLWSTDHVR in prostate cancer cell lines (A) and tumor tissues (B). (A) The peptide
was detected in TMPRSS2-ERG gene fusion positive prostate cancer cell lines (VCaP and NCI-H660), but was not detected in TMPRSS2-ERG
gene fusion negative prostate cancer cell lines (LNCaP, DU145, PC3 and 22RV1). (B) The peptide was detected in 6 out of the 7 TMPRSS2-ERG
gene fusion positive prostate tumor tissues (PT1, PT2, PT4ePT7), but was not detected in the 5 TMPRSS2-ERG gene fusion negative prostate
tumor tissues (XICs not shown). All samples were analyzed in triplicate and one representative XIC for each sample was shown here.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 1 6 9e1 1 8 0 1177presenceof a particular isoformeither, because there are other
“shared”peptides that are detected. In this studyweconfirmed
the concurrent presence of at least two clearly distinguishable
groups of isoforms of ERG protein in the same TMPRSS2-ERGpositive samples, based on our observation that two mutually
exclusive ERG peptides (ITTRPDLPYEPPR and NTDLPYEPPR;
Table 1 and Figure S4) were simultaneously detected in several
samples (Tables 3 and 4). This is the first documentation at the
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 1 6 9e1 1 8 01178protein level of a potential multi-focal origin for prostate can-
cer, driven by distinct TMPRSS2-ERG fusion events or by the
translation of multiple alternative transcripts. The quantita-
tive SRM results on the limited set of peptides are not able to
identify exactly which fusion protein products are expressed
in the samples, however, the detection of certain peptides, as
well as their abundance information, can serve as unique “pro-
files” for the expression status of various TMPRSS2-ERG fusion
protein products in a given sample (Supplementary Figure S7).
The broad range of abundances of the detected ERG pep-
tides (Tables 3 and 4) indicated that multiple isoforms of
ERG protein were potentially expressed at widely variable
levels in TMPRSS2-ERG positive prostate cancer cell lines
and tumor tissues. In addition there are other factors that
could cause variable detection levels of different peptides in
a sample, such as the differences in tryptic digestion effi-
ciency, peptide-specific interference, and endogenous proteo-
lytic cleavage. Nevertheless, the comparison of abundances of
specific peptides across different clinical samples is expected
to provide valuable information for diagnosis or monitoring of
TMPRSS2-ERG prostate cancer. For the sake of determining
ERG over-expression as a result of TMPRSS2-ERG fusion, we
recommend the SRM analysis of peptidesMVGSPDTVGMNYG-
SYMEEK, HMPPPNMTTNER, and VIVPADPTLWSTDHVR which
are shared across almost all possible fusion protein products
and have shown to be the most abundant peptides in either
cell line or tissue samples.
Our results also demonstrated that ERG protein expression
was highly correlated with TMPRSS2-ERG rearrangements
(Table 3, Table 4, and Figure 3). Indeed, Park et al. previously
explored ERG protein expression by immunohistochemistry
and observed high concordance between ERG gene rearrange-
ment and ERG protein expression (Park et al., 2010). Compared
with immunohistochemistry used in the study by Park et al.,
our PRISM-SRM method does not rely on antibodies and
hence, PRISM-SRM was both cost- and time-efficient, and
allowed for obtaining (1) accurate quantification and (2) iso-
form information of ERG protein expressed in the samples.
This information should be valuable for an in-depth under-
standing of the role of ERG protein isoforms in the biology of
prostate cancer. Considering the high sensitivity, high speci-
ficity, and antibody-independent features of the PRISM-SRM
approach, the method is expected to enable simultaneous
quantification of many other protein biomarkers in various
types of biological samples.5. Conclusion
We have successfully quantified the TMPRSS2-ERG gene fusion
proteinproducts inprostate cancer cell lines andprostate tumor
tissuesusinganantibody-independentPRISM-SRMapproach.By
monitoring for multiple unique ERG peptides, we proved that at
least two ERG protein isoforms were simultaneously expressed
in some TMPRSS2-ERG gene fusion positive samples. We also
identified three “signature” peptides MVGSPDTVGMNYGSY-
MEEK, HMPPPNMTTNER, and VIVPADPTLWSTDHVR for detect-
ing general ERG over-expression resulting from TMPRSS2-ERG
fusion. Our results showed that ERG protein expression was
highly correlated with TMPRSS2-ERG gene rearrangement.TMPRSS2-ERG gene fusion transcripts play an important role in
stratifying prostate cancer risk (Tomlins et al., 2011). Our results
indicated that ERGprotein expressionmaybeuseful formolecu-
larly subtyping prostate cancer and prostate needle biopsy eval-
uation (Park et al., 2010). PRISM-SRM measurements provided
not only quantitative, but also isoform-specific information (in-
formation that other technologies are currently “blind” to) about
ERG protein expression in prostate cancer samples. It is antici-
patedthatbroadapplicationof thePRISM-SRMassays inprostate
cancer studieswill further improveourunderstandingof the role
of TMPRSS2-ERG gene fusion in the progression of prostate
cancer.6. Conflict of interest
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